Celltrion, Inc.
Financials
Valuation Metrics
Celltrion, Inc.'s Market Cap is ₩42.3T. At end of 2025 it was ₩40.1T. Ranked #14 of 2,414 in KR market (top 0.6%), #14 of 781 on KOSPI (top 2%), #2 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.9%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 42.29T KRW | KR#14/2,414 Sec#2/231 |
| Revenue | 4.90T KRW | KR#132/2,414 Sec#1/231 |
| Net Income | 1.58T KRW | KR#33/2,414 Sec#2/231 |
| Total Assets | 22.33T KRW | KR#72/2,414 Sec#1/231 |
| Net Assets | 17.35T KRW | KR#34/2,414 Sec#1/231 |
| Employees | 2,901 | KR#106/2,414 Sec#2/231 |
| Value | ||
| P/E | 26.75x | KR#1,294/2,414 Sec#81/231 |
| P/B | 2.44x | KR#2,058/2,414 Sec#157/231 |
| PEG | 0.12x | KR#467/2,414 Sec#25/231 |
| P/S | 8.63x | KR#2,263/2,414 Sec#159/231 |
| EV/EBITDA | 28.97x | KR#1,199/2,414 Sec#74/231 |
| FCF Yield | 1.53% | KR#1,103/2,414 Sec#76/231 |
| Profitability | ||
| ROE | 9.11% | KR#690/2,414 Sec#48/231 |
| ROA | 7.08% | KR#508/2,414 Sec#39/231 |
| Op. Margin | 31.65% | KR#51/2,414 Sec#12/231 |
| Revenue Growth | 30.64% | KR#383/2,414 Sec#38/231 |
| Earnings Growth | 222.61% | KR#226/2,414 Sec#12/231 |
| Financial Health | ||
| Debt Ratio | 28.71% | KR#555/2,414 Sec#62/231 |
| Total Debt | 3.74T KRW | KR#85/2,414 Sec#1/231 |
| FCF | 646.05B KRW | KR#48/2,414 Sec#2/231 |
| Cash | 1.12T KRW | KR#92/2,414 Sec#1/231 |
| Net Debt/EBITDA | 1.69x | KR#810/2,414 Sec#57/231 |
| Dividend | ||
| Div. Yield | 0.39% | KR#1,308/2,414 Sec#84/231 |
| Div. Growth | 0.00% | KR—/2,414 Sec—/231 |
| Performance | ||
| 1Y Return | 11.41% | KR#453/2,414 Sec#27/231 |
| 1M Return | 2.42% | KR#420/2,414 Sec#42/231 |
| From 52W High | -24.01% | KR#284/2,414 Sec#16/231 |
| 1Y MDD | -32.70% | KR#329/2,414 Sec#25/231 |
| Trading | ||
| Volume | 755,576 shares | KR#172/2,414 Sec#9/231 |
| Trading Value | 136.25B KRW | KR#18/2,414 Sec#2/231 |
| Foreign Own. | 25.25% | KR#164/2,414 Sec#5/231 |
| Per Share | ||
| EPS | 6,797 KRW | KR#167/2,414 Sec#8/231 |
| BPS | 74,597 KRW | KR#185/2,414 Sec#11/231 |
Company Info
Celltrion, established in 1991, completed its KOSDAQ listing in 2005 and transferred to the Securities Market in 2018, building a unified corporate structure through the absorption merger of Celltrion Healthcare in 2023. It develops, produces, and sells antibody drugs using biotechnology and animal cell mass culture technology, possessing an 11-product portfolio. The company is strengthening its next-generation antibody drug pipeline through alliances and investments with global biotech companies. Celltrion is headquartered in Yeonsu-gu, Incheon Metropolitan City.